{
  "id": 18233552,
  "title": "Sequencio Therapeutics to Present Cancer Vaccine Data at SITC 2026",
  "url": "https://urgent.news/2026/11/05/sequencio-therapeutics-to-present-cancer-vaccine-data-at-sitc-2026",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-05T02:31:48.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/sequencio-therapeutics-to-present-cancer-vaccine-data-at-sitc-2026-164391.html"
  },
  "original_language": "en",
  "account": "HONG KONG SAR - Sequencio Therapeutics Company Limited, a subsidiary of CK Life Sciences International, announced today that the Society for Immunotherapy of Cancer (SITC) has chosen two of its abstracts for presentation at the upcoming 41st Annual Meeting. The meeting will take place from November 4-8, 2026 in Phoenix, Arizona, USA. Both studies evaluate the Prime–Infiltrate–Ignite–Translate (PINT) translational research framework of Sequencio's cancer vaccines.\n\nThe first study, titled \"Enhanced Anti-tumor Efficacy of an hTROP2 circRNA-LNP Cancer Vaccine (Abstract Number: 583),\" presents results from a preclinical trial examining the combination of Sequencio's hTROP2-targeted circRNA-LNP therapeutic vaccine with anti-PD-1 therapy in two TROP2-positive tumor models. The study found that the vaccine increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumors, leading to significant tumor growth inhibition. This suggests that the vaccine and checkpoint inhibition could be a potent combination strategy for cancer treatment.\n\nThe second study, \"Dual-antigen cancer vaccine co-targeting human PD-L1 and PRAME induces specific immune responses in hPD-1/hPD-L1/HLA-A2.1 mice and inhibits tumor growth in an HLA-A2.1/hPRAME mouse colon cancer model (Abstract Number: 1045),\" evaluates Sequencio's human PD-L1/PRAME dual-antigen vaccine. Results show that the vaccine induced robust PRAME-specific T-cell responses and functional hPD-1/hPD-L1 blockade in humanized models. In the efficacy model, the vaccine achieved 65% tumor growth inhibition and led to increased tumor-infiltrating CD4+ cells and anti-tumor immune responses. Importantly, vaccinated tumor-free mice remained protected against tumor rechallenge, demonstrating durable immune activation. The presentation of these studies at SITC 2026 provides important preclinical evidence supporting the potential of Sequencio's cancer vaccine programs and their alignment with the PINT framework.",
  "summary": "CK Life Sciences subsidiary Sequencio Therapeutics will present new research data from its primary cancer vaccine programmes at the Society for Immunotherapy of Cancer 2026 meeting",
  "key_points": [
    "Sequencio Therapeutics abstracts selected for SITC 2026 meeting",
    "hTROP2 circRNA-LNP vaccine study shows increased T-cell subsets",
    "PD-L1/PRAME dual-antigen vaccine inhibits tumor growth in mice"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}